HU206827B - Process for producing pharmaceutical compositions containing imexone as active component with specifical immunosuppressive activity - Google Patents
Process for producing pharmaceutical compositions containing imexone as active component with specifical immunosuppressive activity Download PDFInfo
- Publication number
- HU206827B HU206827B HU893821A HU382189A HU206827B HU 206827 B HU206827 B HU 206827B HU 893821 A HU893821 A HU 893821A HU 382189 A HU382189 A HU 382189A HU 206827 B HU206827 B HU 206827B
- Authority
- HU
- Hungary
- Prior art keywords
- imexone
- active ingredient
- formulated
- pharmaceutical composition
- cell
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 15
- 230000001506 immunosuppresive effect Effects 0.000 title claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 10
- 230000008569 process Effects 0.000 title claims description 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 26
- 230000035755 proliferation Effects 0.000 claims abstract description 25
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 239000004480 active ingredient Substances 0.000 claims description 24
- 201000010099 disease Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 208000030507 AIDS Diseases 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 206010038997 Retroviral infections Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 230000003844 B-cell-activation Effects 0.000 claims description 2
- 241000607479 Yersinia pestis Species 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract description 12
- BIXBBIPTYBJTRY-UHFFFAOYSA-N imexon Chemical compound NC1=NC(=O)N2CC12 BIXBBIPTYBJTRY-UHFFFAOYSA-N 0.000 abstract description 11
- 229950003978 imexon Drugs 0.000 abstract description 10
- 229940125721 immunosuppressive agent Drugs 0.000 abstract description 10
- 230000004913 activation Effects 0.000 abstract description 5
- 230000001991 pathophysiological effect Effects 0.000 abstract description 2
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000031223 plasma cell leukemia Diseases 0.000 abstract 1
- 208000010626 plasma cell neoplasm Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 22
- 241001465754 Metazoa Species 0.000 description 14
- 210000000952 spleen Anatomy 0.000 description 12
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 9
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 229960002555 zidovudine Drugs 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 210000004989 spleen cell Anatomy 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 206010001513 AIDS related complex Diseases 0.000 description 3
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 230000003460 anti-nuclear Effects 0.000 description 3
- 230000000798 anti-retroviral effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000003327 cancerostatic effect Effects 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000003308 immunostimulating effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 210000004180 plasmocyte Anatomy 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 229920006158 high molecular weight polymer Polymers 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000009826 neoplastic cell growth Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- KOYMTVWMCXDJNV-UHFFFAOYSA-N 1-[(2-methoxy-6-methylpyridin-3-yl)methyl]aziridine-2-carbonitrile Chemical compound COC1=NC(C)=CC=C1CN1C(C#N)C1 KOYMTVWMCXDJNV-UHFFFAOYSA-N 0.000 description 1
- QWMOKSOFGNVFPD-UHFFFAOYSA-N 3-diazobicyclo[3.1.0]hexan-2-one Chemical compound [N-]=[N+]=C1CC2CC2C1=O QWMOKSOFGNVFPD-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000004736 B-Cell Leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 230000006819 RNA synthesis Effects 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000714180 Rauscher mink cell focus-forming virus Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000781 anti-lymphocytic effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 239000003903 antiretrovirus agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical class N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000001177 retroviral effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- RPACBEVZENYWOL-XFULWGLBSA-M sodium;(2r)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate Chemical compound [Na+].C=1C=C(Cl)C=CC=1OCCCCCC[C@]1(C(=O)[O-])CO1 RPACBEVZENYWOL-XFULWGLBSA-M 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Prostheses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3825667A DE3825667A1 (de) | 1988-07-28 | 1988-07-28 | Verwendung von imexon als immunsuppressivum |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUT52378A HUT52378A (en) | 1990-07-28 |
| HU206827B true HU206827B (en) | 1993-01-28 |
Family
ID=6359767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU893821A HU206827B (en) | 1988-07-28 | 1989-07-27 | Process for producing pharmaceutical compositions containing imexone as active component with specifical immunosuppressive activity |
Country Status (14)
| Country | Link |
|---|---|
| EP (1) | EP0352652B1 (enExample) |
| JP (1) | JP2848634B2 (enExample) |
| KR (1) | KR0135757B1 (enExample) |
| AT (1) | ATE117551T1 (enExample) |
| AU (1) | AU619027B2 (enExample) |
| CA (1) | CA1333771C (enExample) |
| DE (2) | DE3825667A1 (enExample) |
| DK (1) | DK175199B1 (enExample) |
| HU (1) | HU206827B (enExample) |
| IE (1) | IE66680B1 (enExample) |
| IL (1) | IL91138A (enExample) |
| PH (1) | PH26684A (enExample) |
| PT (1) | PT91293B (enExample) |
| ZA (1) | ZA895710B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200604579B (en) * | 2003-12-08 | 2007-10-31 | Univ Arizona | Synergistic anti-cancer compositions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2528460A1 (de) * | 1975-06-26 | 1977-01-13 | Boehringer Mannheim Gmbh | Verwendung von l-carboxamido-2- cyan-aziridin als immunstimulans |
| DE2530398A1 (de) * | 1975-07-08 | 1977-01-27 | Boehringer Mannheim Gmbh | Organische verbindung |
| DE2736296A1 (de) * | 1977-08-12 | 1979-02-22 | Boehringer Mannheim Gmbh | Verwendung von 2-cyan-aziridin und seinen derivaten zur immunstimulierung |
-
1988
- 1988-07-28 DE DE3825667A patent/DE3825667A1/de active Granted
-
1989
- 1989-07-21 PH PH38984A patent/PH26684A/en unknown
- 1989-07-21 AT AT89113425T patent/ATE117551T1/de not_active IP Right Cessation
- 1989-07-21 EP EP89113425A patent/EP0352652B1/de not_active Expired - Lifetime
- 1989-07-21 DE DE58908926T patent/DE58908926D1/de not_active Expired - Fee Related
- 1989-07-21 DK DK198903633A patent/DK175199B1/da not_active IP Right Cessation
- 1989-07-24 AU AU38877/89A patent/AU619027B2/en not_active Ceased
- 1989-07-25 CA CA000606620A patent/CA1333771C/en not_active Expired - Fee Related
- 1989-07-27 IL IL9113889A patent/IL91138A/en not_active IP Right Cessation
- 1989-07-27 IE IE244889A patent/IE66680B1/en not_active IP Right Cessation
- 1989-07-27 HU HU893821A patent/HU206827B/hu not_active IP Right Cessation
- 1989-07-27 ZA ZA895710A patent/ZA895710B/xx unknown
- 1989-07-27 PT PT91293A patent/PT91293B/pt not_active IP Right Cessation
- 1989-07-28 JP JP1194417A patent/JP2848634B2/ja not_active Expired - Fee Related
- 1989-07-28 KR KR1019890010705A patent/KR0135757B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| PH26684A (en) | 1992-09-15 |
| DK363389A (da) | 1990-01-29 |
| DE3825667C2 (enExample) | 1991-06-27 |
| IL91138A0 (en) | 1990-03-19 |
| IE892448L (en) | 1990-01-28 |
| HUT52378A (en) | 1990-07-28 |
| AU619027B2 (en) | 1992-01-16 |
| KR900001369A (ko) | 1990-02-27 |
| PT91293A (pt) | 1990-02-08 |
| IL91138A (en) | 1994-10-21 |
| IE66680B1 (en) | 1996-01-24 |
| EP0352652A3 (de) | 1991-09-04 |
| KR0135757B1 (ko) | 1998-04-23 |
| DE3825667A1 (de) | 1990-03-15 |
| ATE117551T1 (de) | 1995-02-15 |
| AU3887789A (en) | 1990-02-01 |
| EP0352652A2 (de) | 1990-01-31 |
| DE58908926D1 (de) | 1995-03-09 |
| CA1333771C (en) | 1995-01-03 |
| JP2848634B2 (ja) | 1999-01-20 |
| EP0352652B1 (de) | 1995-01-25 |
| PT91293B (pt) | 1995-03-01 |
| ZA895710B (en) | 1990-04-25 |
| DK363389D0 (da) | 1989-07-21 |
| DK175199B1 (da) | 2004-07-05 |
| JPH0288521A (ja) | 1990-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH01502027A (ja) | ３’―アジド―２’，３’―ジデオキシウリジン抗レトロウィルス組成物 | |
| JPS62240619A (ja) | 制癌剤 | |
| KR0134376B1 (ko) | 면역 억제제로서 유용한 4-퀴놀린 카르복실산 유도체 | |
| JPH0662407B2 (ja) | 安定化された３―オキシゲルミルプロピオン酸ポリマーを有効成分とする免疫調整剤 | |
| JPH06234637A (ja) | 腫瘍壊死因子アルファを阻害するためのレフルノミドの使用 | |
| NL194430C (nl) | Niet-injecteerbaar farmaceutisch preparaat met anti-kankerwerking. | |
| US5369119A (en) | Use of imexon as an immune suppressive and pharmaceutical compositions containing imexon | |
| CA2672716C (fr) | Nouvelle utilisation therapeutique pour le traitement des leucemies | |
| JPS5849315A (ja) | 抗腫瘍剤 | |
| CA2190750A1 (en) | Arteriosclerosis depressant | |
| US4883808A (en) | Condensation products of cyclic diketones and ascorbic acid as immunomodulatory agents | |
| JP2848634B2 (ja) | 免疫抑制作用を有する医薬 | |
| JPH05504550A (ja) | 免疫抑制剤として有用なピリミジン生合成インヒビター | |
| JPH03501387A (ja) | ケトブチロラクトン及びフリルブチロラクトンを用いて哺乳類の炎症を治療する方法 | |
| JP4781624B2 (ja) | Ｒａｎｔｅｓ誘導剤 | |
| RU2807938C1 (ru) | Применение патулитрина в качестве диуретического средства | |
| RU2816948C1 (ru) | Применение пиностробина в качестве диуретического и креатининуретического средства | |
| JPS61189292A (ja) | ５−フルオロデオキシウリジン誘導体の新規な固溶体及びこれを活性成分として含有する制癌剤 | |
| DE3844839C2 (de) | Verwendung von Imexon als Immunsuppressivum | |
| WO2025184497A1 (en) | Stat3 inhibitors for use in the treatment of cancer | |
| US20060025484A1 (en) | Use of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)urea for treatment of pancreatic carcinomas, soft tissue sarcomas, testicular tumors, lymphomas, thymomas, wilms' tumors, renal carcinomas, melanomas, lung tumors, intracerebral metastases, tumors in the head and neck area and mammary carcinomas | |
| DE3844655A1 (de) | Verwendung von imexon als immunsuppressivum | |
| TW565445B (en) | Cisplatin analogs for cancer treatment | |
| JPS6232722B2 (enExample) | ||
| HK1065253A (en) | Use of glycyrrhizin and its derivatives as rantes inducers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HPC4 | Succession in title of patentee |
Owner name: AUTOONCONA PHARMA GMBH, DE |
|
| MM4A | Lapse of definitive patent protection due to non-payment of fees |